Global Antisense and RNAi Therapeutics Market Outlook to 2023: Rising Adoption as an Effective Option for the Treatment of Many Deadly Diseases - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 19, 2018--The “Global Antisense and RNAi Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The Global Antisense and RNAi Therapeutics Market is projected to grow at a CAGR of 8.67% during the period 2019-2023.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend affecting this market is the growing potential to address multiple therapy areas. Antisense and RNAi therapeutics can regulate the expression of genes inside the cells and they are known to have enough potential to address multiple therapy areas.
According to the report, one driver influencing this market is the high target affinity and specificity of RNAi therapeutics. The global antisense and RNAi therapeutics market is expected to witness a speedy growth owing to rising adoption of antisense and RNAi therapeutics as an effective option for the treatment of many deadly diseases such as cancers and HIV-AIDS.
Further, the report states that one challenge affecting this market is the high price of RNAi drugs. RNAi drugs provide their worth, but at the same time, their exorbitant price makes them unaffordable for a wide variety of patients, which may impede the growth of the market.
Key VendorsAlnylam Pharmaceuticals Bausch Health Biogen Sarepta Therapeutics
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 07: MARKET SEGMENTATION BY TYPEMarket segmentation by type Comparison by type Antisense therapy - Market size and forecast 2018-2023 RNAi therapy - Market size and forecast 2018-2023 Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY APPLICATIONSegmentation by application Cardiovascular diseases Cancer Metabolic disorders
PART 10: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGESMarket drivers Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPEOverview Landscape disruption
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Alnylam Pharmaceuticals Bausch Health Biogen Sarepta Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/gkt92h/global_antisense?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181119005467/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/19/2018 09:58 AM/DISC: 11/19/2018 09:58 AM